Auto logout in seconds.
Continue Logout
In a new study, Eli Lilly's new next-generation weight-loss drug, when combined with the company's GLP-1 drug Zepbound, led to significantly more weight loss than just Zepbound alone, in today's bite-sized hospital and health industry news from the District of Columbia, Indiana, and New Jersey.
- District of Columbia: In a new report, HHS' Office of the Inspector General (OIG) found that fraud related to durable medical equipment providers "has been a long-standing issue in Medicare, putting millions of taxpayer dollars at risk each year." OIG investigated six MA organizations that manage over 20,000 durable medical equipment suppliers and found the MA companies were more lax about supplier requirements compared to the Medicare program. While Medicare requires all suppliers to be enrolled in the program, some suppliers managed by MA companies were not enrolled. MA companies also did not consistently check if out-of-network suppliers were accredited and met state licensure requirements. OIG also criticized CMS in its report, saying the agency did not properly screen suppliers, especially those who are out-of-network. OIG recommended MA organizations monitor their out-of-network suppliers more closely, regularly use CMS' preclusion list for screening, and require all suppliers who bill MA to be enrolled in Medicare. (Wicklund, https://www.healthcaredive.com/news/oig-urges-crackdown-on-equipment-suppliers-in-medicare-advantage/Healthcare Dive, 9/15)
- Indiana: In a new study, Eli Lilly's new next-generation weight-loss drug, when combined with the company's GLP-1 drug Zepbound, led to significantly more weight loss than just Zepbound alone. The new drug, which is called eloralintide, is an injection that mimics the hormone amylin, which helps signal fullness after eating. In a study with 367 participants, patients on the highest dose of Zepbound and eloralintide lost an average of 23.3% of their body weight over roughly 11 months, compared to an average of 14.8% for those on Zepbound alone. Notably, a significant number of patients in the study (between 11% and 27%) dropped out due to side effects. However, Lilly said the high dropout rate was partly due to patients switching to higher doses more quickly than they typically would have due to the study's shorter timeline. "This will be a turning point for the field," said Dan Skovronsky, Lilly's chief scientific officer. "I think this combination will be the most tolerable therapy that we've developed yet for the degree of weight loss that we expect to achieve." (Janin, Wall Street Journal, 9/30)
- New Jersey: Bayer has agreed to sell the rights for its cancer drug Stivarga to Gruenenthal Group for up to $430.7 million. The drug is currently approved to treat advanced forms of metastatic colorectal cancer, hepatocellular carcinoma, and gastrointestinal stromal tumors. It is expected to lose patent protection in the European Union in 2029 and in the United States in 2030. According to Gruenenthal, the acquisition is the latest step in the company's strategy to acquire established medications that serve continuing medical needs, and it expects the deal to increase its 2027 earnings by up to roughly 100 million euros before interest, taxes, depreciation, and amortization. The deal is expected to close by the end of 2026 or early 2027 after customary closing conditions are met. (Calatayud, Wall Street Journal, 9/21)
Don't miss out on the latest Advisory Board insights
Create your free account to access 1 resource, including the latest research and webinars.
Want access without creating an account?
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Become a member to access all of Advisory Board's resources, events, and experts
Never miss out on the latest innovative health care content tailored to you.
Benefits include:
Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
You've reached your limit of free insights
Become a member to access all of Advisory Board's resources, events, and experts
Never miss out on the latest innovative health care content tailored to you.
Benefits include:
Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece
Email ask@advisory.com to learn more
Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board
Never miss out on the latest innovative health care content tailored to you.
Benefits Include:
Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
This is for members only. Learn more.
Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board
Never miss out on the latest innovative health care content tailored to you.
Benefits Include:
Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
